# A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK

> **NCT06990399** · PHASE3 · RECRUITING · sponsor: **Kodiak Sciences Inc** · enrollment: 600 (estimated)

## Conditions studied

- Macular Edema Secondary to Inflammation

## Interventions

- **DRUG:** KSI-101
- **OTHER:** Sham Comparator

## Key facts

- **NCT ID:** NCT06990399
- **Lead sponsor:** Kodiak Sciences Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2027-04
- **Final completion:** 2027-11
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06990399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06990399, "A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06990399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*